It refers to the parallel consultation between European Network for Health Technology Assessment (EUnetHTA) and the European Medicines Agency (EMA). 

As of July 2017, EUnetHTA and the EMA offer parallel consultations on evidence generation plans. This multi-stakeholder procedure, in which Regulators through the Scientific Advice Working Party (SAWP) and health technology assessment bodies (HTABs) work as equal partners, aims to allow medicine developers to obtain feedback from both regulators andHTABs on their development plans to support decision-making on marketing authorization, health technology assessment, and reimbursement of new medicines at the same time.

There is one single procedure for Parallel Consultation which lasts 135 days from the submission of the letter of Intent by the Applicant to the finalisation of the Regulators and HTABs’ recommendations.. The EMA Scientific Advice (SA) Secretariat and EUnetHTA Early Dialogue (ED) Secretariat should be notified simultaneously by the Applicant 2 months prior to the formal procedure start date. The EUnetHTA ED Secretariat facilitates closed HTAs interactions for discussion of respective HTA body positions and HTA coordination throughout the procedure.
A Scientific Officer from EMA is appointed to the procedure. On the HTABs’ side, the EUnetHTA ED Secretariat contacts HTABs to request a response regarding their participation to the procedure. After receipt and validation of the Applicant’s request, on the EUnetHTA side, the Early Dialogue Working Party (EDWP) scrutinizes the request and according to established EDWP criteria, one of the two possible pathways for HTA involvement (consolidated or individual parallel consultation) is decided. 

Indeed, there are two different pathways for HTA involvement the consultation can take: 

Then, the final decision on the parallel consultation pathway and final composition of the Early Dialogue Committee (EDC) are communicated to EMA and Applicant.
For all Parallel Consultations, there is a presubmission phase (with or without a presubmission teleconference), which starts when the Applicant sends the draft briefing package to EMA and EUnetHTA. Comments are provided to the Applicant to optimise and finalise the briefing package before final submission and validation by both EMA and EUnetHTA ED Secretariat.


The Evaluation phase consists in :
-    issuing a list of issue to facilitate the discussion during the face-to-face meeting. Regulators and HTABs proceed with their own assessment and exchange draft lists of issue before the final list of issue is sent to the Applicant. The Applicant can be requested to provide written responses before the face-to-face meeting;
-    the organisation of pre-face-to-face teleconferences between Regulators and HTABs, to exchange upon and understand respective positions of both sides ;
-    the preparation and attendance to the face-to-face meeting between the Applicant, Regulators and HTABs. This meeting aims at discussing issues of concern or disagreement or convergence from Regulators and/or HTABs and potential solutions that could facilitate one trial design or at least one development plan

Finally, the Final Advice Letter is adopted by Regulators and sent to the Applicant and EUnetHTA ED Secretariat while EDC Written (individual or consolidated, depended on the pathway decided) recommendations are finalised on the HTABs’ side.  EUnetHTA ED Secretariat sends the Final Written Recommendations to EMA and the Applicant as a final deliverable.
The advice provided by each stakeholder is not legally binding. EMA Regulators take the Committee for Medicinal Products for Human Use (CHMP) Scientific Advice/Protocol Assistance provided into consideration during the Marketing Authorisation Application (MAA). The Applicant needs to justify fully any deviations from the advice given.
 

Latest Glossary Definitions

Monitoring Plan

Describes the monitoring methods, responsibilities, and requirements for the trial. It includes a brief description of the study, its objectives, and the critical data and study procedures.

The plan describes the reference policies and procedures to follow.

Project Management Plan

The purpose of this document is to define the scope of activities, outline responsibilities (define task and roles) and provide guidance on a specific project.

EUDAMED

Is the European Databank on Medical Devices. It’s a secure, web-based portal that acts as a central hive for the exchange of information between national competent authorities and the European Commission.

ISO14155

International standard addressing good clinical practice for the design, conduct, recording and reporting of clinical investigations carried out in human subjects to assess the safety or performance of medical devices for regulatory purposes.

Redaction

In relation to Policy 70, the process of permanently obscuring CCI or PPD in the clinical documentation submitted to EMA by the applicant/MAH before the documents are published. Tthe redaction should appear as a light blue box with a black 'PPD' label or as a black box with a red 'CCI' label.

Protection of personal data (PPD)

In relation to Policy 70, “Personal data” is any information relating to an identified or identifiable natural person; an identifiable person is one who can be identified, directly or indirectly, in particular by reference to an identification number or to one or more factors specific to his

Informed Consent Form (ICF)

Patients, and/or in specific circumstances their legally designated representative(s), are requested to give written consent before participating in a clinical trial.

Lay person summary (of a clinical trial)

The EU Clinical Trials Regulation 536/2014 (Article 37) requires sponsors to provide summary results of clinical trials in a format understandable to laypersons. These lay person summaries will be made available in the EU Portal and Database.

Pages